PPT-Optimizing Use of Biological Agents in Ulcerative Colitis
Author : tatyana-admore | Published Date : 2018-11-10
Introduction Case 1 What to Do When Conventional Treatment Fails Case 1 What to Do When Conventional Treatment Fails cont Safety of Ibuprofen in Patients With
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Optimizing Use of Biological Agents in U..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Optimizing Use of Biological Agents in Ulcerative Colitis: Transcript
Introduction Case 1 What to Do When Conventional Treatment Fails Case 1 What to Do When Conventional Treatment Fails cont Safety of Ibuprofen in Patients With IBD Case 1 What to Do When Conventional Treatment Fails cont. Ulcerative Colitis. Sarah Hallaj. May 24. th. 2010. Outline. Present my patient. Nutrition assessment. Tests. Ulcerative colitis. Trivia questions. Nutrition focused physical examination: PICTURES!. Ulcerative Colitis. Unknown etiology. Mucosal inflammation. . and ulceration. in the large intestine. Always involves the rectum. Early; Widespread fuzzy, serrated ulcerations. Late; Rigid tube appearance, ‘lead pipe’. Forms 6A and 6B. Potentially Hazardous Biological Agents (PHBA). Students are allowed to conduct research in a very limited capacity using hazardous biologicals. Potentially hazardous biological agents are. Fraud Investigations in Louisiana Department of Children and Families (DCFS). Ted deSaussure. Optimizing Performance in Volatile Times. Background. Large scale fraud investigation conducted in New Orleans involving Secret Service, multiple Federal law enforcement agencies & LA DCFS. the Month:. Extensive . ulcerative colitis with worsening clinical . symptoms. Developed by the CCFA Nurse and Advanced Practice Committee. Author: Keisa M. Lynch, DNP. University of Utah. Instructions. Dr. Omar Mansour. Consultant Colorectal & Laparoscopic . General Surgeon. Assistant Professor of General Surgery. Al-. Balqa. Applied University. FRCS FRCSI FEBC MSc MRCSI. What IS IBD. ? . Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. . Part 2. Crohn’s Disease. . Laparoscopic Colectomy - Results: Patient Outcomes. Conversion Rate 5.9% . Laparoscopy for Ileocolic Crohns. Prospective Randomized Trial 60 pts . Ileo-colic Crohn’s Disease. G SADASIVA RAO . M. . Pharm. , (. Ph.D. ). Asst. Professor & HOD. Dept. . of . Pharmacy . Practice. ,. Hindu college of pharmacy, Guntur, AP.. Definition. Inflammatory bowel disease (IBD) involves . Is It Infectious, Inflammatory, or Ischemic?. Brandon C. Childers, MD. 1. Sarah Wallace Cater, MD. 1. Karen M. Horton, MD. 1. Elliot K. Fishman, MD. 1. Pamela T. Johnson, MD. 1. *. 1. The Russell H. Morgan Department of Radiology and Radiological Science. Amebic colitis is caused by the protozoan parasite . Cases of fulminant amebic colitis are rare, and among them, non-fatal cases are rarer due to the associated high mortality rate. The disease res 1 Ulcerative colitis Description Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectu FatigueFeverWeight loss(often with abdominal pain, presence of blood, pus or mucus) Signs and symptoms of ulcerative colitis can range from mild to severe.Patients with UC may experience ongoing disea Michael Chiorean, MD. IBD Lead – Physician Enterprise Puget Sound. Co-Director, IBD Center - Swedish Medical Group. @mchiorean4. Francis A. Farraye, MD, MSc. Director, Inflammatory Bowel Disease Center. Anders B. Nexoe. 1. , . Bartosz. Pilecki. 1. , Mathias Rathe. 2. , Steffen Husby. 2. , . Uffe. Holmskov. 1. , . Grith. L. Sorensen. 1. 1. Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Download Document
Here is the link to download the presentation.
"Optimizing Use of Biological Agents in Ulcerative Colitis"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents